Free Trial
NASDAQ:HBIO

Harvard Bioscience (HBIO) Stock Price, News & Analysis

Harvard Bioscience logo
$2.11 +0.01 (+0.48%)
(As of 12/20/2024 05:16 PM ET)

About Harvard Bioscience Stock (NASDAQ:HBIO)

Key Stats

Today's Range
$2.06
$2.15
50-Day Range
$2.03
$2.82
52-Week Range
$1.99
$5.56
Volume
322,348 shs
Average Volume
123,591 shs
Market Capitalization
$92.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Harvard Bioscience Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
26th Percentile Overall Score

HBIO MarketRank™: 

Harvard Bioscience scored higher than 26% of companies evaluated by MarketBeat, and ranked 568th out of 652 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Harvard Bioscience.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Harvard Bioscience is -6.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Harvard Bioscience is -6.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Harvard Bioscience has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.03% of the outstanding shares of Harvard Bioscience have been sold short.
  • Short Interest Ratio / Days to Cover

    Harvard Bioscience has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Harvard Bioscience has recently increased by 20.32%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Harvard Bioscience does not currently pay a dividend.

  • Dividend Growth

    Harvard Bioscience does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.03% of the outstanding shares of Harvard Bioscience have been sold short.
  • Short Interest Ratio / Days to Cover

    Harvard Bioscience has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Harvard Bioscience has recently increased by 20.32%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Harvard Bioscience has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Computer and Technology companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Harvard Bioscience this week, compared to 12 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Harvard Bioscience insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.00% of the stock of Harvard Bioscience is held by insiders.

  • Percentage Held by Institutions

    80.87% of the stock of Harvard Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Harvard Bioscience's insider trading history.
Receive HBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter.

HBIO Stock News Headlines

Harvard Bioscience, Inc. (NASDAQ:HBIO) Short Interest Update
Did You See Trump’s Bombshell Exec. Order 001?
Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."
Harvard Bioscience Reveals Q3 2024 Financial Results
Harvard Bioscience Announces Third Quarter 2024 Financial Results
See More Headlines

HBIO Stock Analysis - Frequently Asked Questions

Harvard Bioscience's stock was trading at $5.35 at the start of the year. Since then, HBIO shares have decreased by 60.6% and is now trading at $2.11.
View the best growth stocks for 2024 here
.

Harvard Bioscience, Inc. (NASDAQ:HBIO) issued its quarterly earnings results on Tuesday, November, 2nd. The medical instruments supplier reported $0.06 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.06. The medical instruments supplier had revenue of $29.66 million for the quarter, compared to the consensus estimate of $28.10 million. Harvard Bioscience had a negative net margin of 14.57% and a negative trailing twelve-month return on equity of 4.64%.

The following companies are subsidiaries of Harvard Bioscience: Data Sciences International.

Harvard Bioscience's top institutional shareholders include Harvey Partners LLC (6.22%), Royce & Associates LP (3.33%), Geode Capital Management LLC (2.09%) and State Street Corp (1.64%). Insiders that own company stock include James W Green and Alan I Edrick.
View institutional ownership trends
.

Shares of HBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Harvard Bioscience investors own include YETI (YETI), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Alphabet (GOOG), STAG Industrial (STAG) and Tesla (TSLA).

Company Calendar

Last Earnings
11/02/2021
Today
12/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:HBIO
CUSIP
41690610
Employees
490
Year Founded
1901

Profitability

Net Income
$-3,410,000.00
Pretax Margin
-13.67%

Debt

Sales & Book Value

Annual Sales
$97.73 million
Cash Flow
$0.21 per share
Book Value
$1.71 per share

Miscellaneous

Free Float
39,691,000
Market Cap
$92.03 million
Optionable
Optionable
Beta
1.27

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:HBIO) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners